Tredegar Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Tredegar Corporation for the period ended March 31, 2005. Tredegar operates in three primary segments: Film Products, Aluminum Extrusions, and Therics (biotechnology). The company reported 38,625,794 shares of common stock outstanding as of April 29, 2005.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenues (Sales) | $232,757,000 | $195,919,000 |
| Net Income | $5,550,000 | $2,429,000 |
| Earnings Per Share (Diluted) | $0.14 | $0.06 |
| Gross Profit Margin | 12.2% | 14.0% |
| Operating Cash Flow | $4,485,000 | $58,947,000 |
| Total Debt | $117,917,000 | $103,452,000 (Dec 2004) |
| Cash and Equivalents | $25,572,000 | $22,994,000 (Dec 2004) |
Note: Q1 2004 operating cash flow was significantly boosted by a one-time income tax refund of approximately $59 million related to a prior year asset sale.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 18.8% year-over-year, driven by a 21.7% increase in Film Products (new product growth, price increases) and a 15.5% increase in Aluminum Extrusions (higher metal costs passed to customers).
- Profitability: Net income more than doubled to $5.6 million. This improvement is largely due to a significant reduction in restructuring charges compared to Q1 2004. Q1 2004 included a $9.6 million charge for the shutdown of an aluminum facility, whereas Q1 2005 included a net gain of $1.6 million on the shutdown of a film facility.
- Segment Performance:
- Film Products: Operating profit from ongoing operations rose 16% to $11.6 million despite higher resin costs.
- Aluminum Extrusions: Operating profit from ongoing operations declined 19% to $3.0 million due to Canadian Dollar appreciation ($900k impact) and higher energy/distribution costs.
- Therics: Operating loss narrowed to $1.8 million from $2.5 million due to cost reductions.
- Costs: R&D expenses dropped to $2.8 million from $4.3 million, partly due to reclassifying certain Therics costs to operating expenses as products commercialized.
Guidance, Outlook, and Risks
- Outlook: Management expects 2005 results in both Film Products and Aluminum Extrusions to exceed 2004 levels. A price increase announced in April 2005 is expected to offset higher costs in Aluminum Extrusions.
- Capital Expenditures: Expected to be $55 million in Film Products and $13 million in Aluminum Extrusions for the full year 2005.
- Restructuring Savings: Ongoing shutdowns and restructurings (New Bern film plant, Aurora aluminum plant, R&D consolidation) are expected to generate approximately $8 million in annual cost savings.
- Risks and Contingencies:
- Raw Material Volatility: Profit margins are sensitive to resin (Film) and aluminum/energy (Extrusions) prices. While pass-through agreements cover ~65% of Film sales, there is a 90-day lag.
- Customer Concentration: Film Products relies heavily on Procter & Gamble (P&G), which comprised 27% of net sales in 2004.
- Therics Uncertainty: Therics has incurred losses since inception; profitability depends on successful commercialization and regulatory approvals.
- Foreign Exchange: Appreciation of the Canadian Dollar negatively impacted Aluminum Extrusions profits by approximately $900,000 in Q1 2005.
Investor Verification Checklist
- Verify the sustainability of the $1.6 million gain on the New Bern facility shutdown versus the $9.6 million charge in the prior year.
- Monitor the effectiveness of the April 2005 price increase in Aluminum Extrusions to offset energy and currency headwinds.
- Assess the timeline for Therics to achieve profitability and the status of FDA clearances for new orthobiologic products.
- Review the impact of rising resin prices on Film Products margins, specifically regarding the 90-day lag in cost pass-through agreements.
- Confirm the company's compliance with debt covenants, specifically the leverage ratio (currently 1.47x vs. 3.00x limit) and interest coverage (15.31x vs. 2.50x limit).